Trial Profile
A Phase 2b Extension Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ataluren (Primary)
- Indications Cystic fibrosis
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors PTC Therapeutics
- 07 Aug 2014 New trial record